Noncoding RNome as Enabling Biomarkers for Precision Health.
Int J Mol Sci
; 23(18)2022 Sep 08.
Article
in English
| MEDLINE | ID: covidwho-2039865
ABSTRACT
Noncoding RNAs (ncRNAs), in the form of structural, catalytic or regulatory RNAs, have emerged to be critical effectors of many biological processes. With the advent of new technologies, we have begun to appreciate how intracellular and circulatory ncRNAs elegantly choreograph the regulation of gene expression and protein function(s) in the cell. Armed with this knowledge, the clinical utility of ncRNAs as biomarkers has been recently tested in a wide range of human diseases. In this review, we examine how critical factors govern the success of interrogating ncRNA biomarker expression in liquid biopsies and tissues to enhance our current clinical management of human diseases, particularly in the context of cancer. We also discuss strategies to overcome key challenges that preclude ncRNAs from becoming standard-of-care clinical biomarkers, including sample pre-analytics standardization, data cross-validation with closer attention to discordant findings, as well as correlation with clinical outcomes. Although harnessing multi-modal information from disease-associated noncoding RNome (ncRNome) in biofluids or in tissues using artificial intelligence or machine learning is at the nascent stage, it will undoubtedly fuel the community adoption of precision population health.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
MicroRNAs
/
RNA, Long Noncoding
Type of study:
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Year:
2022
Document Type:
Article
Affiliation country:
Ijms231810390
Similar
MEDLINE
...
LILACS
LIS